Literature DB >> 24985976

ChIP-seq analysis of androgen receptor in LNCaP cell line.

Sifeng Tao1, Haifei He, Qiang Chen.   

Abstract

The aim of this study was to screen target genes and gene functions of androgen receptor (AR) in LNCaP cell line by ChIP-seq data analysis. We downloaded the gene expression profile GSE14092 from Gene Expression Omnibus database and selected ChIP-seq data (GSM353644) of AR stimulated by androgen R1881 (R1881 stimulation group) and the ChIP-seq data (GSM353643) of AR without R1881 stimulation (control group). MACS peak calling software was used to identify the AR binding cites. After target genes selection and function analysis, motif finding analysis was utilized to predict the AR co-located transcription regulation factors, and we analyzed their functions through GO enrichment analysis. Total 27202 and 2730 AR binding sites were detected in the R1881 stimulation group and the control group, respectively and 398 and 58 target genes were identified in R1881 stimulation group and control group, respectively. Based on GO enrichment analysis, 20 biological processes which AR regulated in the LNCaP cells were enriched, including xenobiotic metabolic process, positive regulation of interleukin-2 production and cellular response to sterol etc. We finally identified 99 transcription factors with high motif enrichment significant levels, and the enrichment of AR co-located transcription factors was significantly enriched in the biological process of regulation of cell proliferation in which 13 transcription factors were involved (FOXJ1, FOXM1, NF1, SOX2, HOXD13, FOXO1, FOXP3, FOXO4, SOX9, PGR, DBP, JUN and TLX1). The analysis of AR target genes and gene functions help us to elucidate the mechanism of the prostate cancer on a molecular level. In addition, it will pave the way to effective therapies for prostatic cancer. However, further experiments are still needed to confirm our results.

Entities:  

Year:  2014        PMID: 24985976     DOI: 10.1007/s11033-014-3511-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  42 in total

1.  Identification of transcription factor binding sites derived from transposable element sequences using ChIP-seq.

Authors:  Andrew B Conley; I King Jordan
Journal:  Methods Mol Biol       Date:  2010

2.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

Review 4.  Understanding Forkhead box class O function: lessons from Drosophila melanogaster.

Authors:  Oscar Puig; Jaakko Mattila
Journal:  Antioxid Redox Signal       Date:  2010-10-20       Impact factor: 8.401

Review 5.  Prostate cancer: an emerging threat to the health of aging men in Asia.

Authors:  Ling Zhang; Bao-Xue Yang; Hai-Tao Zhang; Jin-Guo Wang; Hong-Liang Wang; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2011-05-09       Impact factor: 3.285

Review 6.  Pathological and molecular aspects of prostate cancer.

Authors:  Angelo M DeMarzo; William G Nelson; William B Isaacs; Jonathan I Epstein
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

7.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

8.  Advances in the treatment of metastatic prostate cancer.

Authors:  Simon Chowdhury; Roger Kirby
Journal:  Practitioner       Date:  2013-04

9.  Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Authors:  Susan L Ettinger; Richard Sobel; Tanis G Whitmore; Majid Akbari; Dawn R Bradley; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Design and analysis of ChIP-seq experiments for DNA-binding proteins.

Authors:  Peter V Kharchenko; Michael Y Tolstorukov; Peter J Park
Journal:  Nat Biotechnol       Date:  2008-11-16       Impact factor: 54.908

View more
  3 in total

1.  Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.

Authors:  Atish D Choudhury; Anna C Schinzel; Maura B Cotter; Rosina T Lis; Katherine Labella; Ying Jie Lock; Francesca Izzo; Isil Guney; Michaela Bowden; Yvonne Y Li; Jinal Patel; Emily Hartman; Steven A Carr; Monica Schenone; Jacob D Jaffe; Philip W Kantoff; Peter S Hammerman; William C Hahn
Journal:  Cancer Res       Date:  2016-11-29       Impact factor: 12.701

2.  Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.

Authors:  L Fan; G Peng; N Sahgal; L Fazli; M Gleave; Y Zhang; A Hussain; J Qi
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

3.  Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

Authors:  Denise Chronscinski; Srujana Cherukeri; Fraser Tan; Nicole Perfito; Joelle Lomax; Elizabeth Iorns
Journal:  PeerJ       Date:  2015-09-15       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.